On a disclosed basis, sales were KRW 10.1 billion in 2022, KRW 6.97 billion in 2023, KRW 6.46 billion in 2024 and KRW 10.5 billion in 2025. Sales fell 30.9% in 2023 and 7.3% in 2024, which made 2024 the smallest year of 2022 to 2025. Sales rose 62.4% in 2025, which made it the largest year.
Operating losses over the same period were KRW 9.68 billion, KRW 10.1 billion, KRW 12.3 billion and KRW 11.7 billion. The deficit widened in 2023 and 2024 and narrowed in 2025. Operating margins were -96.0%, -144.7%, -189.9% and -111.3%, with 2024 the most negative.
For 2024, the company attributed the weak results to intensifying competition in genomic analysis, continued R&D spending and general economic uncertainty.
The net loss attributable to controlling shareholders was KRW 9.38 billion, KRW 9.68 billion, KRW 12.3 billion and KRW 17.4 billion, a loss in each of the four years from 2022 to 2025, with 2025 the largest. The net loss including non-controlling interests was reported at the same levels.
Operating cash flow was -KRW 12 billion, -KRW 8.13 billion, -KRW 10.7 billion and -KRW 7.08 billion, with the 2025 outflow the smallest. The debt ratio climbed from 5.9% to 17.5%, 48.8% and then 332.3%.
Quarterly sales are volatile: KRW 2.15 billion in the third quarter of 2025, KRW 3.13 billion in the fourth quarter (up 45.7% from the prior quarter), KRW 2.39 billion in the first quarter of 2026 (down 23.9%), KRW 3.61 billion in the second quarter (up 51.2%) and KRW 2.29 billion in the third quarter (down 36.6%).
Third-quarter 2026 sales were up 6.3% from a year earlier. The operating loss was KRW 2.33 billion, KRW 2.96 billion, KRW 2.05 billion, KRW 4.59 billion and KRW 3.24 billion across the same five quarters, with the second quarter of 2026 the largest loss of the five.
The net loss attributable to controlling shareholders was KRW 2.45 billion, KRW 8.13 billion, KRW 2.03 billion, KRW 7.75 billion and KRW 3.7 billion, a loss in all five quarters. The last four quarters together total KRW 21.6 billion.